Zika virus NS1 ELISA Duo Reference: ARG30277 The mosquito-borne Zika virus (ZIKV) is prompting worldwide concern due to its connection to neurological disorders including microcephaly. Zika virus belongs to the flavivirus family which encompasses Dengue, yellow fever, West Nile and more different viruses. The connection of neurological disorders creates a need for further research into the ZIKV infection and therapeutic approaches. For more ZIKA virus antibody and ZIKA virus antibody Duo products, please refer to Choose the Best ZIKA Virus Antibodies
Osocimab Reference: HY-P99794 Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.
Fresolimumab Reference: HY-P99020 Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases .
Sotrovimab Reference: HY-P99340 Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease.
Porgaviximab Reference: HY-P99784 Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
Atoltivimab Reference: HY-P99343 Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
Bifarcept Reference: HY-P99478 Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life.